THALLOUS CHLORIDE TL 201
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Dec 1982
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
THALLOUS CHLORIDE TL 201 by Bracco is 201 with no carrier added accumulates in viable myocardium in a manner analogous to that of potassium. First approved in 1982.
Drug data last refreshed 14h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Thallous Chloride Tl 201 is a radioactive diagnostic imaging agent approved in 1982 for myocardial perfusion imaging. It accumulates in viable myocardium analogous to potassium and visualizes regional coronary perfusion, identifying areas of infarction as 'cold' regions and transient ischemia during stress testing. This nuclear cardiology agent is administered via injection to assess coronary artery disease and myocardial viability.
LOE Approaching
As a legacy diagnostic agent approaching loss of exclusivity with moderate competitive pressure (30/100), commercial teams are likely rightsizing and focusing on operational efficiency rather than growth initiatives.
Mechanism of Action
201 with no carrier added accumulates in viable myocardium in a manner analogous to that of potassium. Experiments in healthy subjects using labeled microspheres have shown that the myocardial distribution of thallous chloride Tl 201 correlates with regional perfusion. In clinical studies, Thallous…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on Thallous Chloride Tl 201 offers limited career growth opportunity; roles are primarily operational and defensive in nature. Professionals joining this product should expect focus on cost management, compliance, and lifecycle extension rather than innovation or commercial expansion.
Worked on THALLOUS CHLORIDE TL 201 at Bracco? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.